Indefinite Delivery Contract SPE2DR25D9639

The federal contract IDV awarded to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The IDC has a ceiling value of $499,999,999 and is valid through November 2026. Under this contract, DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, will provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The contract covers branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This contract positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, enabling the direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The original solicitation, which is expected to be issued in March 2024, is for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts. The intent is to make multiple primary supplier awards for separate regions (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) and one award for a backup supplier to support normal day-to-day operations, planned and unplanned contingency, Prime Vendor Readiness (PVR), and War Readiness Materiel (WRM) for the Defense Health Agency, Department of Defense, United States Coast Guard, and other government agencies. The estimated total value for all regions and options is $30.3 billion, and the award will be made on a lowest price technically acceptable (LPTA) basis.